Steinhorn, RH. Pharmacotherapy for pulmonary hypertension. Pediatr Clin North Am
2012; 59: 1129–1146.
Porta, NF, Steinhorn, RH. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clin Perinatol
2012; 39: 149–164.
Buxton, N, Flannery, T, Wild, D, Bassi, S. Sildenafil (Viagra)-induced spontaneous intracerebral haemorrhage. Br J Neurosurg
2001; 15: 347–349.
Samada, K, Shiraishi, H, Aoyagi, J, Momoi, MY. Cerebral hemorrhage associated with sildenafil (Revatio) in an infant. Pediatr Cardiol
2009; 30: 998–999.
Baquero, H, Soliz, A, Neira, F, Venegas, ME, Sola, A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatr
2006; 117: 1077–1083.
Steinhorn, RH. Diagnosis and treatment of pulmonary hypertension in infancy. Early Hum Dev
2013; 89: 865–874.
Steinhorn, RH, Kinsella, JP, Pierce, C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr
2009; 155: 841–847 e1.
Mourani, PM, Sontag, MK, Ivy, DD, Abman, SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr
2009; 154: 379–384. e1-2.
Limjoco, J, Paquette, L, Ramanathan, R, Seri, I, Friedlich, P. Changes in mean arterial blood pressure during sildenafil use in neonates with meconium aspiration syndrome or sepsis. Am J Ther
2015; 22: 125–131.
Vassalos, A, Peng, E, Young, D, et al. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. Anaesthes
2011; 66: 472–480.
Ahsman, MJ, Witjes, BC, Wildschut, ED, et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed
2010; 95: F109–F114.
Mukherjee, A, Dombi, T, Wittke, B, Lalonde, R. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther
2009; 85: 56–63.
Laughon, MM, Benjamin, DK Jr, Capparelli, EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol
2011; 4: 643–652.
Laughon, MM, Benjamin, DK Jr. Mechanisms to provide safe and effective drugs for children. Pediatr
2014; 134: e562–e563.
Spitzer, AR, Ellsbury, DL, Handler, D, Clark, RH. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system – tools for “meaningful use” in continuous quality improvement. Clin Perinatol
2010; 37: 49–70.
Olsen, IE, Groveman, SA, Lawson, ML, Clark, RH, Zemel, BS. New intrauterine growth curves based on United States data. Pediatr
2010; 125: e214–e224.
Samiee-Zafarghandy, S, Smith, PB, van den Anker, JN. Safety of sildenafil in infants. Pediatr Crit Care Med
2014; 15: 362–368.
McLaughlin, VV, McGoon, MD. Pulmonary arterial hypertension. Circulation
2006; 114: 1417–1431.
Galie, N, Ghofrani, HA, Torbicki, A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med
2005; 353: 2148–2157.
Shekerdemian, LS, Ravn, HB, Penny, DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res
2004; 55: 413–418.
Farrow, KN, Groh, BS, Schumacker, PT, et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res
2008; 102: 226–233.
Vargas-Origel, A, Gomez-Rodriguez, G, Aldana-Valenzuela, C, et al. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol
2010; 27: 225–230.
Kearns, GL. Selecting the proper pediatric dose: it is more than size that matters. Clin Pharmacol Ther
2015; 98: 238–240.
Holford, N. Dosing in children. Clin Pharmacol Ther
2010; 87: 367–370.
Thakkar, N, Gonzalez, D, Cohen-Wolkowiez, M, et al. An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. J Perinatol
2016; 36: 744–747.
Barst, RJ, Beghetti, M, Pulido, T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation
2014; 129: 1914–1923.
Barst, RJ, Ivy, DD, Gaitan, G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation, 125: 324–334.
Dodgen, AL, Hill, KD. Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. Drug Healthc Patient Saf
2015; 7: 175–183.
Kraemer, U, Wildschuth, E, Tibboel, D. “Out of the blue”-safety and efficacy of pulmonary hypertension treatment in childhood. Pediatr Crit Care Med
2014; 15: 377–378.
England, A, Wade, K, Smith, PB, Berezny, K, Laughon, M. Optimizing operational efficiencies in early phase trials: the Pediatric Trials Network experience. Contemp Clin Trials
2016; 47: 376–382.